- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07822334
A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
A Phase I, Randomized, Investigator and Participant-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of RO7830698 in Healthy Participants (Part 1) and in Participants With Chronic Obstructive Pulmonary Disease (Part 2)
This study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple doses of RO7830698 in healthy participants and participants with chronic obstructive pulmonary disease (COPD).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Study Contact Backup
- Name: Reference Study ID Number: WP46321 https://forpatients.roche.com/ No attachments to email below.
- Phone Number: 888-662-6728 (U.S. and Canada)
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
Greater Manchester
-
Wythenshawe, Greater Manchester, United Kingdom, M23 9QZ
- Recruiting
- Medicines Evaluation Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All participants:
- Body mass index (BMI) between 18 and 32 kilograms per meter square (kg/m2)
- Agreement to adhere to the contraception requirements
Part 1:
- Absence of evidence of any active or chronic disease
Part 2:
- Confirmed diagnosis of COPD for > 6 months, as defined by the Global Initiative for Chronic obstructive Lung Disease (GOLD) guidelines
- Using maintenance inhaled therapy that may include inhaled corticosteroids (ICS) and/or long-acting β-agonist (LABA) and/or long-acting muscarinic antagonist (LAMA) as separate inhaler(s) or in combination preparation(s)
- Current smoker or ex-smoker with a tobacco history of >= 10 pack years
Exclusion Criteria:
- Pregnant or breastfeeding, or planning to become pregnant during the study or within the timeframe in which contraception is required
- Current or chronic history of clinically significant liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert syndrome or asymptomatic gallstones) or cirrhosis
- Known history of allergy to drugs or other substances, or clinically significant, acute, and/or uncontrolled allergic disease
- Known or suspected history of immunosuppression
- History of recurrent severe infections and underlying conditions predisposing participant to infections
- History of disseminated herpes simplex infection, or recurrent (> 1 episode) or disseminated herpes zoster
- Autoimmune disease requiring systemic immunosuppressive therapy
- History of or presence of any clinically significant unstable cardiovascular disease
- Treatment with medications targeting the same pathways as RO7830698, immunomodulatory/ immunosuppressive therapy, or licensed biologics for COPD and asthma within protocol-defined periods
- Positive results for hepatitis B infection, human immunodeficiency virus infection, or hepatitis C infection at the Screening visit
- Evidence of tuberculosis infection or disease
- Participation in any clinical study of a drug or medical device within protocol-defined periods
- Any other conditions that may affect providing informed consent or study protocol adherence, or if study participation may affect study results or participant safety
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Part 1: Single Ascending Dose (SAD)
Healthy participants will receive single doses of RO7830698 or placebo. |
Participants will receive placebo as per the schedule described in the protocol.
Other Names:
Participants will receive RO7830698 as per the schedule described in the protocol. |
|
Experimental: Part 2: Multiple Ascending Dose (MAD)
Participants with COPD will receive multiple doses of RO7830698 or placebo. |
Participants will receive placebo as per the schedule described in the protocol.
Other Names:
Participants will receive RO7830698 as per the schedule described in the protocol. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part 1: Incidence and Severity of Adverse Events (AEs)
Time Frame: Up to approximately 50 weeks
|
Up to approximately 50 weeks
|
|
Part 2: Incidence and Severity of AEs
Time Frame: Up to approximately 44 weeks
|
Up to approximately 44 weeks
|
|
Part 1: Incidence of Dose-limiting Adverse Events (DLAEs)
Time Frame: Up to approximately 50 weeks
|
Up to approximately 50 weeks
|
|
Part 2: Incidence of DLAEs
Time Frame: Up to approximately 44 weeks
|
Up to approximately 44 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part 1 and Part 2: Plasma Concentration of RO7830698
Time Frame: Part 1: Up to approximately 50; Part 2: Up to approximately 44 weeks
|
Part 1: Up to approximately 50; Part 2: Up to approximately 44 weeks
|
|
Part 1: Bioavailability (F) of RO7830698
Time Frame: Up to approximately 50 weeks
|
Up to approximately 50 weeks
|
|
Part 1: Area Under the Concentration-Time Curve From Time 0 To Infinity (AUC inf) of RO7830698
Time Frame: Up to approximately 50 weeks
|
Up to approximately 50 weeks
|
|
Part 1 and Part 2: Incidence of Anti-Drug Antibodies (ADAs) to RO7830698
Time Frame: Part 1: Up to approximately 50; Part 2: Up to approximately 44 weeks
|
Part 1: Up to approximately 50; Part 2: Up to approximately 44 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WP46321
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.